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Background: Due to recent improvements in colorectal cancer survival, patient-reported outcomes, including
health-related quality of life and satisfaction with care, have become well-established endpoints to determine the
impact of the disease on the lives of patients.
The aim of this study is to determine prospectively, in a cohort of colorectal cancer incident cases: a) health-related
quality of life, b) satisfaction with hospital-based care, and c) functional status. A secondary objective is to
determine whether diagnostic/therapeutic delay influence quality of life or patients’ satisfaction levels.
Methods/design: Single-centre prospective follow-up study of colorectal cancer patients diagnosed during the
period 2011–2012 (n = 375).
This project was approved by the corresponding ethics review board, and informed consent is obtained from each
patient. After diagnosis, patients are interviewed by a trained nurse, obtaining information on sociodemographic
characteristics, family history of cancer, first symptoms, symptom perception and reaction to early symptoms.
Quality of life is assessed with the EORTC QLQ-C30 and QLQ-CR29 questionnaires, and patients’ satisfaction with
care is determined using the EORTC IN-PATSAT32. Functional status is measured with the Karnofsky Performance
Status Scale.
Clinical records are also reviewed to collect information on comorbidity, tumour characteristics, treatment, hospital
consultations and exploratory procedures.
Symptoms-to-diagnosis interval is defined as the time from the date of first symptoms until the cytohistological
confirmation of cancer. Treatment delay is defined as the time between diagnosis and surgical treatment.
All the patients will be followed-up for a maximum of 2 years. For survivors, assessments will be re-evaluated at one
and two years after the diagnosis.
Multiple linear/logistic regression models will be used to identify variables associated with the patients’ functional
status, quality of life and satisfaction with care score. Changes in quality of life over time will be analysed with linear
mixed-effects regression models.
Discussion: The results will provide a deeper understanding of the impact of colorectal cancer from a more
patient-centred approach, allowing us to identify groups of patients in need of additional attention, as well as areas
for improvement. Special attention will be given to the relationship between diagnostic/therapeutic delay and
patients’ quality of life and satisfaction with the care received.
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Colorectal cancer remains a significant cause of morbidity
and mortality throughout the world. It is the third most
commonly diagnosed cancer in males and the second in
females, with over 1.2 million incident cases and 608,700
deaths estimated to have occurred in 2008 [1]. In recent
years, colorectal cancer death rates have decreased in sev-
eral Western countries [2], a result of screening policies,
the reduction of risk factors and improved treatment [3].
Estimates of long-term cancer survival rates in Europe,
published by the EUROCARE-4 project, show a five-year
relative survival of colorectal cancer patients ranging
from 64% in Switzerland to 44% in Poland [4]. In Spain,
this figure stands at 61.5%. Ten-year relative survival is
only about 5 percentage points lower, which indicates a
very good prognosis for those patients who are still alive
after five years in all countries.
Because of these recent improvements in survival,
patient-reported outcomes, including health-related
quality of life (QOL) and satisfaction with care, have be-
come well-established outcomes in cancer patients,
along with traditional endpoints of tumour response and
survival [5]. Patients with cancer may also exhibit func-
tional impairment as a direct result of the disease or
treatment-related sequelae [6]. Moreover, a positive rela-
tionship between quality of life data and the survival of
cancer patients was established [7].
However, despite its importance, quality of life is not
routinely measured in the care of patients with cancer.
One of the difficulties lies in choosing the appropriate
instrument to measure patients’ quality of life. Question-
naires developed by the European Organisation for Re-
search and Treatment of Cancer (EORTC) [8,9] and the
FACT-C (Functional Assessment of Cancer Therapy-
Colorectal) [10] have become the most used in research
studies.
Several studies have been published in the last few
years analysing early [11-18] and long-term [19-28] qual-
ity of life in colorectal cancer patients. In general, these
studies show that QOL deteriorates early after treatment
but gradually improves if there is no recurrence or pro-
gression of the disease. In the long-term, the QOL of
colorectal cancer survivors appears to be comparable to
the general population. However, survivors have a
slightly worse physical QOL, suffer from bowel symp-
toms and cancer-related distress, and have worse depres-
sion scores [29]. Some factors, such as higher age, a
lower income or a higher number of comorbidities are
clearly associated with lower levels of QOL scores. How-
ever, results regarding the effects of other cancer-related
factors, such as the presence of a stoma, stage or treat-
ment regimens seem to be inconclusive [29].
On the other hand, the assessment of patient satisfac-
tion has also been recognised as a key indicator of healthcare quality, especially in oncology, where patients are
subjected to increasingly complex treatments, exhaustive
follow-ups, and numerous visits to hospital. It has been
demonstrated that measurement of patient satisfaction re-
quires the use of multi-item scales to address the different
dimensions of satisfaction. The European Organisation for
Research and Treatment of Cancer (EORTC) Quality of
Life Group recently developed the EORTC INPATSAT32,
a questionnaire to assess the perception cancer patients
have of the quality of their hospital-based care [30]. The
INPATSAT32 is an instrument that makes it possible to
measure patients’ perception of the quality of medical
care, nursing care and care organisation and services re-
ceived in the hospital. It has been developed and tested in
a cross-cultural context, therefore allowing for compari-
sons among several hospitals or health systems in different
countries. The psychometric properties of the Spanish ver-
sion of the INPATSAT32 have been investigated in 80 can-
cer patients with different tumour sites [31], but to the best
of our knowledge there are no papers determining satisfac-
tion with care exclusively in colorectal cancer patients.
Over the last few years, our group has participated in
two multicentre projects in colorectal cancer patients.
We have been investigating whether diagnosis and thera-
peutic delay, as well as different follow-up strategies, are
associated with a higher survival rate in colorectal can-
cer patients [32,33]. Since studies in other cancer loca-
tions suggest that a long total delay may influence QOL
and survival [34], in this project we aim to investigate in
greater detail the association between diagnostic delay,
treatment delay and follow-up strategies with subse-




To determine the following in colorectal cancer incident
cases, at the time of diagnosis and at 12 and 24 months
during the follow-up period:
a) Health-related quality of life




To identify those factors affecting colorectal cancer pa-
tients’ quality of life, satisfaction with the hospital-based
care, and their functional status. In particular:
a) To determine whether diagnosis delay, treatment
delay and different follow-up strategies influence
patients’ quality of life and satisfaction with the
quality of the hospital-based care.
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stage at diagnosis are associated with quality of life
and functional status in patients with colorectal
cancer.
c) To determine the impact of colostomy on quality of
life in patients with colorectal cancer.
Methods/design
Design
Single-centre prospective follow-up study of colorectal can-
cer patients diagnosed at the Complexo Hospitalario
Universitario A Coruña (A Coruña, Spain) during the
period 2011–2012. Incident cases with anatomopatho-
logical confirmation of colorectal cancer according to the
International Classification of Diseases (ICD) 9th revision
(codes 153 and 154) are included. Prevalent or recurrent
cases are excluded, together with cases of multiple cancers,
cases that are only dealt with in private hospitals, cases
detected through colorectal cancer screening, and cases di-
agnosed in another hospital but which are referred for
treatment to the hospital where the study is conducted.
Data collection
Eligible patients are identified from the Department of
Pathology within one month of diagnosis. At an initial
interview with a trained nurse, patients are informed about
the aims and characteristics of the study. After signing the
Informed Consent Form, information is obtained from pa-
tients regarding their sociodemographic characteristics,
family history of cancer, first symptoms attributable to can-
cer perceived by the patient, symptom perception and re-
action to early symptoms. At the same time, patients are
asked to complete the questionnaires concerning their
health-related quality of life and satisfaction with hospital
care. The patients’ functional impairment is also evaluated
using Karnofsky Performance Status.
In the case of patients qualifying for curative surgical
treatment, the initial interview is performed in the month
following discharge after surgery. Patients subjected only
to palliative procedures are interviewed within three
months of the diagnosis. All of them will be followed-up
for a maximum of 2 years, until December 2013. For sur-
vivors, health-related quality of life and functional status
assessments will be re-evaluated by means of a personal
interview with a trained nurse at one and two years after
the diagnosis during the study period.
Clinical records are also reviewed to collect information
about comorbidity at diagnosis (Charlson comorbidity
index), tumour characteristics at diagnosis (site according
to ICD-9th, tumour size, histological grade, TNM stage,
location of metastases and infiltration of adjacent organs),
treatment received (surgery, chemotherapy and/or radi-
ation therapy), hospital consultations related to the colo-
rectal cancer and exploratory procedures in the follow-up.Occurrence of the following incidents in the follow-up is
also registered: local recurrence, development of metasta-
ses, appearance of a new tumour, and mortality.
Symptoms-to-diagnosis interval is defined as the time
elapsed from the date the patient perceived the first
symptoms until the cytohistological confirmation of the
diagnosis of cancer (date of biopsy or direct surgery).
Treatment delay is defined as the interval from date of
diagnosis to date of treatment (i.e., date of surgery, date
of preoperative or postoperative radiotherapy or chemo-
therapy or date of palliative treatment). For those pa-
tients who do not receive any treatment, the date of the
visit closest to the decision not to treat the patient will
be recorded.
Surveillance strategies will be classified based on the fre-
quency of follow-up and the investigations performed, tak-
ing into account: a) history and physical examinations, b)
serum carcinoembryonic antigen (CEA) determinations,
c) imaging examinations (ecographies, positron emission
tomographies, computed tomographies, magnetic reso-
nances), and d) endoscopy explorations (colonoscopies or
rectoscopies).
Health-related quality of life
Health-related quality of life, the main outcome of this
study, is assessed with the Quality of Life Questionnaire
Core 30 (QLQ-C30) (version 3.0) [8] and the colorectal
cancer-specific quality of life questionnaire module (QLQ-
CR29) [35], developed by the European Organisation for
Research and Treatment of Cancer (EORTC). These ques-
tionnaires have been translated and validated for use in
Spain [36,37].
The EORTC QLQ-C30 is a generic cancer health-
related quality of life questionnaire, which has to be
supplemented by disease-specific modules for each type
of cancer or tumour location. The EORTC QLQ-C30
consists of 30 items and includes a scale measuring the
global health status/health-related quality of life, 5 func-
tioning scales (physical, role, emotional, cognitive and
social), 3 symptom scales (fatigue, nausea/vomiting and
pain), and 6 single-item scales (dyspnea, insomnia, appe-
tite loss, constipation, diarrhoea and financial impact).
The QLQ-CR29 is a colorectal cancer disease–specific
module consisting of 29 items. These are grouped into 4
functioning scales (body image, anxiety, weight and sexual
interest) and 18 symptom scales (urinary symptoms, stool
characteristics, gastrointestinal symptoms, pain and other
symptomatology) [9]. Items related to gastrointestinal
symptoms are collected differently in stoma and non-
stoma patients. Problems associated with sexual activity
are evaluated differently for men and women, with a sep-
arate item for each gender.
The items on both questionnaires will be scaled and
scored using the recommended EORTC procedures [38].
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to each scale, raw scores will be linearly transformed to
a scale ranging from 0 to 100, with a higher score
representing a higher (better) level of functioning or a
higher (worse) level of symptoms. According to EORTC
scoring guidelines, this procedure is only applicable to
those patients with at least half of the items answered
for each of the scales. In that case, any items with miss-
ing values will be ignored when making the calculations.
Satisfaction with hospital-based care
Patient satisfaction with care is assessed by means of the
validated Spanish version of the EORTC IN-PATSAT32
questionnaire [30,31]. This questionnaire was developed
by the EORTC Quality of Life Group for assessing cancer
patients’ perception of the quality of hospital-based care.
The EORTC IN-PATSAT32 is composed of 32 items
organised into eleven multi-item scales and three single
items assessing cancer patients’ perception of the quality
of hospital doctors and nurses, as well as selected as-
pects of the care organisation and hospital environment.
Each question is administered using a 5-category Likert
response scale (“poor”, “fair”, “good”, “very good” or
“excellent”).
The dimensions measured include doctors’ and nurses’
technical skills, interpersonal skills, information provision,
and availability; satisfaction with other hospital staff inter-
personal skills and information provision; exchange of in-
formation with the care team; waiting-time; hospital
access; hospital comfort; and overall satisfaction with care.
Following the standard scoring procedure for the EORTC
IN-PATSAT32, all scores will be linearly transformed to a
0–100 scale, with higher scores reflecting a higher level of
satisfaction.
Functional status
Functional status of colorectal cancer patients is assessed
by means of the Karnofsky Performance Status Scale
(KPS) [39]. The KPS is an 11-point rating scale which
ranges from normal functioning (100) to dead (0), used
to assess patients’ physical functional level related to
cancer and its treatment.
Sample size
Sample size is limited by both the duration of the study
and the number of incident colorectal cancer patients
diagnosed per year. During the period 2011–2012 ap-
proximately n = 500 patients will be diagnosed of colo-
rectal cancer. Assuming a non-response rate of 25%, a
sample size of n = 375 patients is expected.
Based on their 0–100 scoring system, and using the
range rule of thumb, a standard deviation of 25 points
(one quarter of the range score) is assumed for the final
punctuations of the EORTC QLQ-C30, QLQ-CR29 andIN-PATSAT32 questionnaires. Therefore, a sample size
of n = 375 patients will allow us to estimate mean values
with a precision of ±2.6 for a 95% confidence interval.
Working with a power of 80% and an alpha of 0.05,
score differences of 8 points between groups of patients
will be detected as statistically significant, assuming an
exposure of 50% to the variable of interest. This sample
size will also allow detecting as statistically significant
(p ≤ 0.05) correlation coefficients ≥0.15 among the stud-
ied variables and the questionnaires scores.Statistical analysis
Descriptive analyses will be performed for all variables.
Continuous variables will be reported using means ±
standard deviations (SD) or median (interquartile range).
For dichotomous/categorical variables, absolute numbers
and percentages will be computed, together with their
95% confidence intervals.
Health-related quality of life, satisfaction with care and
functional status scores will be compared according to pa-
tients’ characteristics and disease variables. The compari-
son of means will be carried out using Student’s t test,
Mann–Whitney test, analysis of variance or the Kruskall-
Wallis test as appropriate. The association of qualitative
variables will be carried out using Chi-square statistics.
The correlation among quantitative variables will be
assessed using Spearman’s Rho correlation coefficient, due
to the expected non-normal distribution of the question-
naires scores and in order to detect nonlinear relatioships.
In the multivariate analysis, multiple linear and logistic
regression models will be used to identify those variables
independently associated with patients’ functional status
after the diagnosis, quality of life and satisfaction with
care scores. Separate regressions will be conducted for
each of the three outcomes. Box-Cox normalizing trans-
formations will be used when necessary to ensure the
normality assumption in the linear regression model.
Finally, evolution of quality of life at one and two years
from diagnosis will be analysed based on the change
from baseline scores for each time point. Significance of
the changes will be assessed using the Wilcoxon signed
ranks test. Clinical relevance will be analyzed by means
of the minimal important difference (MID), effect sized,
and standard error of measurement (SEM). Information
provided by the developers of the EORTC QLQ-C30
about what could be considered as a MID will be used.
Therefore, a mean change score of 5 to 10 will be a “lit-
tle” change, about 10 to 20 a “moderate” change, and
more than 20 a large change. Cohen’s guidelines for
interpreting small (effect size 0.2-0.49), moderate (effect
size 0.5-0.79), and large (effect size ≥0.5) will also be
considered. Finally, a value greater than 1 SEM will be
considered as clinically significant.
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on the same patients, we will be in a repeated measures
context. Longitudinal QOL will be analysed with a linear
mixed-effects regression model. More specifically, the
relationship of QOL with time will be determined using
a random coefficients model, which generalizes linear re-
gression techniques to allow for repeated observations.
These models take into account the correlation within
observations on the same subject and allow for inclusion
of data on subjects who have only partial follow-up with-
out imputing missing data.
Therefore, a linear random coefficients regression model
will be performed, with QOL scores over time as the
dependent variable. The relationship between QOL and
time will be modeled by including a quantitative time ef-
fect (months since diagnosis) as a covariate in the model,
fitting patient effect and patient*time interaction as ran-
dom effects. In addition to the effect of time on the QOL
outcome measures, we will incorporate other factors into
the regression models, in order to adjust for those vari-
ables of interest and potential confounding factors such
as: sociodemographic variables, diagnosis/treatment delay,
follow-up strategies, comorbidy, TNM stage at diagnosis,
or presence of colostomy.
Two-sided tests will be used, and p-values < 0.05 will
be considered as statistically significant. Statistical ana-
lyses will be performed using SPSS for Windows (ver-
sion 19.0, SPSS Inc., Chicago, Illinois) and R (version
2.12.2). Apart from performing an analysis of all of the
patients, the patients with colon cancer and patients
with rectal cancer will be analysed independently.
Ethics
The study will be carried out according to the Good
Clinical Practice guidelines of the Helsinki declaration.
Informed consent is obtained from each patient to take
part in the study and to review their clinical records.
This project was approved by the corresponding ethics
review board (Clinical Research Ethical Committee of
Galicia, decision 2010/304).
Discussion
Health-related quality of life, as well as other patient-
related outcomes, is now considered an important end-
point in oncology studies [5]. Measurement of quality of
life in colorectal cancer patients provides valuable infor-
mation regarding the burden of the disease and side
effects of cancer therapies. In addition, there is also evi-
dence that a better QOL is associated with a prolonged
survival of patients with cancer [7]. Therefore, improving
the quality of life of these patients may lead to an im-
provement of their prognosis.
Understanding the characteristics associated to quality
of life may help clinicians to identify patients at risk forpoor quality of life, as well as to plan medical, psycho-
logical or social interventions to improve the patient’s
well-being. Gender, age, income, education level and so-
cial network have been identified as general determi-
nants of quality of life in colorectal cancer survivors.
Other health-related factors, such as a higher body mass
index or having more comorbidities also seems to be as-
sociated to poorer quality of life. Among cancer-related
factors, no association was found with stage, while few
studies have evaluated the relationship between different
treatment regimens and quality of life [29].
Inconclusive results were observed concerning the ef-
fects of a permanent colostomy on quality of life [29,40].
In this sense, a Cochrane review comparing the quality of
life in patients with or without permanent colostomy
showed that it was not possible to draw conclusions
whether the quality of life of stoma patients is poorer than
that of non-stoma patients or not [40].
Information about patient satisfaction is also import-
ant in assessing the quality of health services. Studying
the satisfaction of oncologic patients is especially im-
portant, because of the complexity of their treatments
and the intensive monitoring they usually undergo. Until
now, few studies have assessed the satisfaction of cancer
patients by means of a validated instrument like the
EORTC IN-PATSAT32 [30,36,41,42]. Published studies
include oncologic patients with different locations, and
we have not found any that only refer to colorectal can-
cer patients [30,36,41,42].
Although it is popularly assumed that delay has a sig-
nificant and harmful impact on survival, recent reviews
suggest that there is no association between diagnostic
or therapeutic delays and prognosis in colorectal cancer
patients [43,44]. Some studies even found counterintui-
tive results, showing that patients with short diagnostic
intervals had higher mortality rates than patients with
long diagnostic intervals [43]. This is the so-called
“waiting time paradox,” and has also been reported for
other types of cancer [45].
Quality of life and patient satisfaction present an alter-
native way for evaluating consequences of experiencing
delay among these patients. Since a recent study has found
a negative association between diagnostic delay and qual-
ity of life and patient satisfaction in gynaecologic cancer
patients [34], we may hypothesize that long diagnosis
delay could be an indicator of poorer quality of life and
lower satisfaction levels in colorectal cancer patients.
This study will prospectively determine the quality of life
of patients with colorectal cancer, and related variables. Its
results will allow a deeper understanding of the impact of
the disease from a more patient-centred approach. It will
also allow us to recognize significant quality-of-life predic-
tors, and as a result, to identify subgroups of patients with
special needs. We will also determine the satisfaction of
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as well as potential predictors of their satisfaction level. By
identifying background or organisational factors associated
with patient satisfaction, it will be possible to determine
groups of patients in need of additional attention, as well
as areas for improvement. Special attention will be given
to the relationship between diagnostic or therapeutic delay
and patients’ quality of life and satisfaction levels.
The key strengths of this study include its longitudinal
prospective design, the use of well-established instru-
ments, and the large amount of information recorded
from each patient. However, the results could be limited
by the response rate and the proportion of participants
who do not complete all of the assessments. The possi-
bility of non-random dropout is also an important meth-
odological issue. Evidently, the people who did not
respond to the questionnaires may be different to those
who did. Non-responders and those who die during
follow-up could have lower quality of life than re-
sponders; therefore the reported QOL could overesti-
mate the QOL of patients with colorectal cancer. The
opposite could also occur, if patients with a good quality
of life decide not to respond. Moreover, non-response
may also affect the identification of predictors of QOL
and satisfaction levels. We will try to maximize the re-
sponse rate by performing a personal interview with
each patient, in which QOL and satisfaction with care
questionnaires will be completed.
Other limitations could be the single-centre nature and
short study duration. Although single-centre studies sim-
plify data collection and typically deal with a less heteroge-
neous population (therefore diminishing confounding),
they have potentially limited external validity. A multicentre
study could be more efficient and would have the advantage
of increased generalizability of the results. On the other
hand, this study will only analyse the early impact of colo-
rectal cancer on the patients’ quality of life, in the first and
second year after diagnosis. Additional follow-up will be re-
quired to investigate long-term QOL and related variables.Abbreviations
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